Navigation Links
Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol
Date:12/19/2013

THOUSAND OAKS, Calif., Dec. 19, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Phase 3 DESCARTES (Durable Effect of PCSK9 Antibody CompARed wiTh PlacEbo Study) study evaluating the long-term 52-week safety and efficacy of evolocumab for the treatment of high cholesterol met its primary endpoint of percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 52. The mean percent reduction in LDL-C, or "bad" cholesterol, was consistent with the results observed in the 52-week analysis of the Phase 2 OSLER (Open Label Study of Long TERm Evaluation Against LDL-C) study.

Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove LDL-C from the blood.1

The DESCARTES study evaluated safety, tolerability and efficacy in 901 patients with high LDL-C and a range of cardiovascular risk. Background lipid-lowering therapy was optimized to one of four treatment groups (diet alone; diet plus atorvastatin 10 mg; diet plus atorvastatin 80 mg; and diet plus atorvastatin 80 mg plus ezetimibe 10 mg) for individual patients based on their LDL-C and cardiovascular risk. Patients with a fasting LDL-C ≥ 75 mg/dL were then randomized to receive monthly subcutaneous evolocumab 420 mg or placebo in combination with background lipid-lowering therapy.

Evolocumab significantly reduced LDL-C, as measured by the accepted standard, preparative ultracentrifugation, from baseline at week 52 compared to placebo.  LDL-C reduction at week 12 was consistent with the long-term efficacy at week 52.

Safety was balanced across treatment groups. The most common adverse events (> 5 percent
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen Announces 2014 First Quarter Dividend
2. Amgen To Present At The Oppenheimer 24th Annual Healthcare Conference
3. Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
4. Amgens Third Quarter 2013 Revenues Increased 10 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 16 Percent To $1.94
5. Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
6. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
7. Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgens Acquisition of Onyx
8. Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
9. Amgen To Participate At Citis 8th Annual Biotech Conference
10. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
11. Amgen to Highlight New Data at Upcoming ESC Congress 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
(Date:12/17/2014)... and SAN DIEGO , Dec. 17, 2014 ... ; AEX: PHIA) and Volcano Corporation (NASDAQ: VOLC ... for cardiovascular applications, today announced that they have entered into ... commence a tender offer to acquire all of the issued ... or a total equity purchase price of USD 1 billion ...
(Date:12/17/2014)... , Dec. 17, 2014  Strategic Health Services, Inc. ... solutions, today announced a strategic agreement with QualCare, Inc., a ... New Jersey regional marketplace.  This agreement will ... health and wellness solutions QualCare brings to its clients ... surrounding region. QualCare plans cover more ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3
... 2012  InterMune, Inc. (NADSAQ: ITMN) today reported ... announced its decision granting the additional benefit ... treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF).  ... 4 (not quantifiable benefit)  in the rating ...
... March 15, 2012 Reportlinker.com announces that ... in its catalogue: ... http://www.reportlinker.com/p0578259/Vaccines---Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This market research report ... actual market situation, trends and future outlook ...
Cached Medicine Technology:Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 2Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 3Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 4Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 5Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 6Vaccines - Asia 2
(Date:12/19/2014)... Energy Textiles is excited to announce ... the world’s leading responsive textile, can now be ... are a number of benefits to wearing Celliant, ... balanced body temperature; which can lead to enhanced ... athletic performance; and overall wellness. In addition, the ...
(Date:12/19/2014)... These vanadium reserves are mostly found ... 151,000 tons of vanadium were produced globally in 2013, ... increased at 6.7% AAGR during the period from 2001 ... being the largest consumer, accounted for more than 90% ... alloy and the chemical industry. , View Full Report ...
(Date:12/19/2014)... (HealthDay News) -- The intestinal bacteria that cause inflammatory ... may be inherited, researchers report. The findings, published ... help in efforts to prevent the disease and treat ... study authors added. "The intestinal bacteria, or ,gut ... have a big impact on your health for the ...
(Date:12/19/2014)... News) -- The cost of cancer treatment can cause ... finds. Researchers examined data from 1,000 people in ... or lung cancer. Of those patients, almost 900 had ... 100 had advanced cancer. Nearly half of the ... bills, which was linked with a poorer health-related quality ...
(Date:12/19/2014)... B. E. Smith, the only full-service leadership ... retained to lead a national chief financial officer ... Park, Colo. The top executive search firm in the ... than 900 healthcare executives into organizations. , Estes ... access hospital and level IV trauma center, with a ...
Breaking Medicine News(10 mins):Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3
... of British Columbia have identified new breast cancer genes ... and form the basis of next-generation treatments. Researchers ... based on the genetic fingerprint of a tumour. Many ... cancer biology, allowing doctors to predict whether a tumour ...
... and quality-of-life issues should be considered essential elements of ... point of breast cancer diagnosis. However, for women suffering ... other medically underserved areas around the world, this fundamental ... To address these issues, many of the world,s ...
... HealthDay Reporter , TUESDAY, April 17 (HealthDay News) ... they enter the Part D "donut hole," the seniors ... essential for heart health, new research shows. "We looked ... three and half months during a year. While we didn,t ...
... Carina Storrs HealthDay Reporter , TUESDAY, April 17 ... could one day help diagnose teens with depression. To ... depression. Then they tested the markers in a small group ... distinguish the teens with major depression from those without depression. ...
... , HOUSTON - Scientists who developed a technology for identifying ... surface have found a way to penetrate the outer membrane ... inside the cell. In a paper published today online ... at The University of Texas MD Anderson Cancer Center reports ...
... , , , , , ... AUDIO: New research in half siblings adds to evidence that even though autism is far ... Click here for more information. , , , ... , , , , , , ...
Cached Medicine News:Health News:Scientists rewrite rulebook on breast cancer in landmark global study 2Health News:Scientists rewrite rulebook on breast cancer in landmark global study 3Health News:International breast health global summit will focus on supportive care and quality of life 2Health News:International breast health global summit will focus on supportive care and quality of life 3Health News:Seniors Stop Taking Heart Drugs In Medicare 'Donut Hole' 2Health News:Seniors Stop Taking Heart Drugs In Medicare 'Donut Hole' 3Health News:Researchers Develop Blood Test for Depression 2Health News:Researchers Develop Blood Test for Depression 3Health News:Scientists tailor cell surface targeting system to hit organelle ZIP codes 2Health News:Scientists tailor cell surface targeting system to hit organelle ZIP codes 3Health News:Study of half siblings provides genetic clues to autism 2Health News:Study of half siblings provides genetic clues to autism 3Health News:Study of half siblings provides genetic clues to autism 4Health News:Study of half siblings provides genetic clues to autism 5
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: